LXEO
NASDAQ · Biotechnology
Lexeo Therapeutics Inc
$5.52
-0.02 (-0.36%)
Financial Highlights (FY 2025)
Revenue
110.56M
Net Income
17.37M
Gross Margin
32.2%
Profit Margin
15.7%
Rev Growth
+16.0%
D/E Ratio
0.49
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 32.2% | 32.2% | 32.2% |
| Operating Margin | 16.3% | 14.8% | 15.9% |
| Profit Margin | 15.7% | 14.9% | 15.9% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 110.56M | 98.68M | 97.87M |
| Gross Profit | 35.58M | 31.76M | 31.50M |
| Operating Income | 18.01M | 14.65M | 15.53M |
| Net Income | 17.37M | 14.67M | 15.60M |
| Gross Margin | 32.2% | 32.2% | 32.2% |
| Operating Margin | 16.3% | 14.8% | 15.9% |
| Profit Margin | 15.7% | 14.9% | 15.9% |
| Rev Growth | +16.0% | -2.8% | +7.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 195.78M | 189.07M | 226.04M |
| Total Equity | 402.34M | 414.62M | 418.87M |
| D/E Ratio | 0.49 | 0.46 | 0.54 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 19.93M | 19.03M | 18.02M |
| Free Cash Flow | 11.85M | 8.63M | 11.57M |